CD437 is a retinoic acid receptor gamma (RARγ)-selective retinoid agonist shown to effectively inhibit growth and induce apoptosis of a variety of cancer cells. Two forms of dose-dependent action have been reported for this molecule. One mechanism enables induction of apoptosis by a receptor-independent pathway and the other is regulated by a receptor-dependent pathway and is shown to suppress cell differentiation. More recently, Liu, et al. demonstrated the significance of retinoic acid (RA) signaling in reprogramming somatic cells to induced pluripotent stem (iPS) cells. Treatment of mouse embryonic fibroblasts (MEFs) with CD437 early in the reprogramming process significantly increases reprogramming efficiency up to 20 fold. This suggests promoting RA signaling with CD437 may have important implications in reprogramming to a ground-state pluripotency (naïve stem cells).